<DOC>
	<DOCNO>NCT02619071</DOCNO>
	<brief_summary>Adult acute myeloid leukemia ( AML ) heterogeneous hematologic malignancy associate poor prognosis , especially relapse . High-throughput genomic study highlight importance molecular alteration pathophysiology , clinical evolution treatment response AML . In addition , identification specific gene mutation target specific inhibitor , open way personalized treatment . However , limited number gene mutation druggable actionable , highlight need additional information guide treatment choice . Among , new Drug Screening Tests ( DST ) allow screen library hundred drug ex-vivo patient-derived AML cell . Combination genomic pharmacologic approach might therefore improve prediction drug effect . There urgent need bring approach clinic feasibility trial necessary incorporate treatment strategies.The propose study prospective multicentre feasibility study combine `` chemo-genomic '' approach patient advance AML .</brief_summary>
	<brief_title>ChEmo-Genomics Based Treatment Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Age &gt; 18 year Diagnosis acute myeloid leukemia accord WHO classification Refractory relapse disease ECOG performance status &lt; 3 Life expectancy &gt; 3 month Written inform consent Affiliation French Social Security System . Diagnosis Acute Promyelocytic Leukemia . Patients deprive liberty place authority tutor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>acute myeloid leukemia- refractory AML- relapse AML- precision medecine-</keyword>
</DOC>